SKIN

Company Overview — What Does Beauty Health Co Do?

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California. Beauty Health Co (SKIN) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Andrew Stanleick and employs approximately 1,030 people. With a market capitalization of $119M, SKIN is one of the notable companies in the Healthcare sector.

Beauty Health Co (SKIN) Stock Rating — Reduce (April 2026)

As of April 2026, Beauty Health Co receives a Reduce rating with a composite score of 26.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.SKIN ranks #3,832 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Beauty Health Co ranks #647 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SKIN Stock Price and 52-Week Range

Beauty Health Co (SKIN) currently trades at $0.91. The stock lost $0.01 (1.6%) in the most recent trading session. The 52-week high for SKIN is $2.69, which means the stock is currently trading -66.3% from its annual peak. The 52-week low is $0.78, putting the stock 16.2% above its annual trough. Recent trading volume was 157K shares, suggesting relatively thin trading activity.

Is SKIN Overvalued or Undervalued? — Valuation Analysis

Beauty Health Co (SKIN) carries a value factor score of 21/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.84x, versus the sector average of 2.75x. The price-to-sales ratio is 0.38x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, SKIN trades at 16.50x EV/EBITDA, versus 6.34x for the sector.

At current multiples, Beauty Health Co trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Beauty Health Co Profitability — ROE, Margins, and Quality Score

Beauty Health Co (SKIN) earns a quality factor score of 27/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -32.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -3.9% versus the sector average of -33.1%.

On a margin basis, Beauty Health Co reports gross margins of 62.2%, compared to 71.5% for the sector. The operating margin is -14.2% (sector: -66.1%). Net profit margin stands at -7.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -22.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SKIN Debt, Balance Sheet, and Financial Health

Beauty Health Co has a debt-to-equity ratio of 719.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.66x, suggesting adequate working capital coverage. Total debt on the balance sheet is $363M. Cash and equivalents stand at $219M.

SKIN has a beta of 1.50, meaning it is more volatile than the broader market — a $10,000 investment in SKIN would be expected to move 49.8% more than the S&P 500 on any given day. The stability factor score for Beauty Health Co is 18/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Beauty Health Co Revenue and Earnings History — Quarterly Trend

In TTM 2026, Beauty Health Co reported revenue of $297M and earnings per share (EPS) of $-0.08. Net income for the quarter was $-20M. Gross margin was 62.2%. Operating income came in at $-42M.

In FY 2025, Beauty Health Co reported revenue of $301M and earnings per share (EPS) of $-0.08. Net income for the quarter was $-10M. Gross margin was 65.3%. Revenue grew -10.0% year-over-year compared to FY 2024. Operating income came in at $-21M.

In Q3 2025, Beauty Health Co reported revenue of $71M and earnings per share (EPS) of $-0.09. Net income for the quarter was $-11M. Gross margin was 64.6%. Revenue grew -10.3% year-over-year compared to Q3 2024. Operating income came in at $-6M.

In Q2 2025, Beauty Health Co reported revenue of $78M and earnings per share (EPS) of $0.16. Net income for the quarter was $20M. Gross margin was 62.8%. Revenue grew -13.7% year-over-year compared to Q2 2024. Operating income came in at $-3M.

Over the past 8 quarters, Beauty Health Co has demonstrated a growth trajectory, with revenue expanding from $91M to $297M. Investors analyzing SKIN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SKIN Dividend Yield and Income Analysis

Beauty Health Co (SKIN) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SKIN Momentum and Technical Analysis Profile

Beauty Health Co (SKIN) has a momentum factor score of 19/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 38/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 47/100 reflects moderate short selling activity.

SKIN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Beauty Health Co (SKIN) ranks #647 out of 838 stocks based on the Blank Capital composite score. This places SKIN in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SKIN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SKIN vs S&P 500 (SPY) comparison to assess how Beauty Health Co stacks up against the broader market across all factor dimensions.

SKIN Next Earnings Date

No upcoming earnings date has been announced for Beauty Health Co (SKIN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SKIN? — Investment Thesis Summary

The quantitative profile for Beauty Health Co suggests caution. The quality score of 27/100 flags below-average profitability. The value score of 21/100 indicates premium valuation. Momentum is weak at 19/100, a headwind for near-term performance. High volatility (stability score 18/100) increases portfolio risk.

In summary, Beauty Health Co (SKIN) earns a Reduce rating with a composite score of 26.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SKIN stock.

Related Resources for SKIN Investors

Explore more research and tools: SKIN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SKIN head-to-head with peers: SKIN vs AZN, SKIN vs SLGL, SKIN vs VMD.